Meeting
2017 Gastrointestinal Cancers Symposium
Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.
Authors
Zachary D. Horne
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Zachary D. Horne , Weijing Sun , Michael K. Gibson , Arjun Pennathur , James D. Luketich , Brian J Karlovits , Dwight Earl Heron , Joel S. Greenberger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 160)
DOI
10.1200/JCO.2017.35.4_suppl.160
Abstract #
160
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.
First Author: Richard Francis Dunne
Poster
2014 ASCO Annual Meeting
Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced esophageal squamous cell carcinoma?
First Author: Qixun Chen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity.
First Author: Ronan Andrew Mc Laughlin
Poster
2020 Gastrointestinal Cancers Symposium
Retrospective comparison of neoadjuvant chemoradiation (nCRT) +/- surgery using the CROSS trial regimen and definitive chemoradiation (dCRT) with carboplatin (C) and paclitaxel (P) in esophageal (EC), and gastroesophageal junction cancer (GEJC) in Canada.
First Author: Sidra Khalid